Leqvio (Inclisiran) Regulatory Status: US, EU, Canada, and UK

How Inclisiran Works: A First-in-Class siRNA for Cholesterol

Inclisiran represents a distinct pharmacological class from monoclonal antibody PCSK9 inhibitors like evolocumab (Repatha) and alirocumab (Praluent). Rather than binding circulating PCSK9 protein, inclisiran uses RNA interference to silence the gene that produces PCSK9 inside hepatocytes. This is a molecular-level distinction with practical consequences.

The drug is conjugated to triantennary N-acetylgalactosamine (GalNAc), which binds asialoglycoprotein receptors on liver cells with high specificity 1. Once internalized, the siRNA duplex loads into the RNA-induced silencing complex (RISC), where it catalytically degrades PCSK9 messenger RNA. Because a single RISC-loaded strand can cleave multiple mRNA transcripts, the effect persists for months. That durability is what allows a twice-yearly dosing schedule rather than the biweekly or monthly injections required by monoclonal antibodies.

In the pooled ORION-10 and ORION-11 trials (N=3,178 combined), inclisiran 284 mg reduced LDL-C by 52.3% at day 510 compared to placebo, with consistent reductions observed across dosing intervals 1. The time-averaged LDL-C reduction from day 90 through day 540 was 50.5% in ORION-10 (ASCVD patients) and 49.9% in ORION-11 (ASCVD or ASCVD-risk equivalent patients) 1. Injection-site reactions occurred in 5% of inclisiran-treated patients versus 0.7% on placebo. These were mostly mild and transient.

US FDA Approval: December 2021

The FDA approved Leqvio on December 22, 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering 2. The approval was based on three Phase III ORION trials. Patients must be on maximally tolerated statin therapy, with or without other lipid-lowering agents.

A notable feature of the US label: Leqvio is administered only by a healthcare professional. It cannot be self-injected at home. The FDA label specifies subcutaneous injection of 284 mg at initiation, again at 3 months, and then every 6 months 3. This healthcare-professional-only requirement shapes how the drug fits into US clinical workflows, typically administered during cardiology or primary care office visits.

The FDA's approval did not include a cardiovascular outcomes claim. The ORION-4 trial (NCT03705234), a 15,000-patient event-driven outcomes study, is expected to provide data on whether inclisiran's LDL-C reduction translates into reduced major adverse cardiovascular events (MACE) 4. Until those results are available, the prescribing rationale rests on the well-established relationship between sustained LDL-C lowering and cardiovascular risk reduction demonstrated by prior statin and PCSK9-inhibitor outcomes trials.

US reimbursement remains complex. Leqvio's wholesale acquisition cost was set at approximately $3,250 per injection ($6,500 annually). Because it requires in-office administration, it is billed under the medical benefit (Medicare Part B) rather than the pharmacy benefit (Part D), which creates different prior authorization pathways than those clinicians manage for evolocumab or alirocumab 5.

EU EMA Authorization: December 2020

The European Medicines Agency granted marketing authorization for Leqvio on December 9, 2020, making the EU the first major market to approve inclisiran 6. The approved indication is broader than the US label: treatment of adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet 6.

The EMA indication allows use in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant or for whom a statin is contraindicated. This wording gives European prescribers more flexibility than the US label regarding statin background therapy.

The Committee for Medicinal Products for Human Use (CHMP) cited the ORION-9 (HeFH), ORION-10, and ORION-11 trials in its positive opinion. In ORION-9 (N=482), patients with HeFH on maximally tolerated statins achieved a 39.7% reduction in LDL-C at day 510 versus placebo 7. The slightly lower magnitude in HeFH versus non-HeFH populations reflects the higher baseline PCSK9 production driven by LDL receptor mutations in these patients.

Individual EU member states handle pricing and reimbursement independently. Germany's Gemeinsamer Bundesausschuss (G-BA) assessed inclisiran under the AMNOG process. France's Haute Autorité de Santé evaluated it separately, with reimbursement discussions reflecting each country's willingness-to-pay thresholds.

UK NICE Recommendation and NHS England Access

The UK's National Institute for Health and Care Excellence (NICE) recommended inclisiran in September 2021 through Technology Appraisal Guidance TA733, specifically for adults with primary hypercholesterolemia or mixed dyslipidemia 8. What makes the UK market distinct is the population-health commissioning model NHS England adopted.

NHS England established a national commissioning policy that positions Leqvio within a broader lipid management pathway. The approach targets patients whose LDL-C remains above specific thresholds despite optimized oral therapy, including those with ASCVD, HeFH, or very high cardiovascular risk. Under this framework, the drug is administered in designated lipid management clinics, GP surgeries with appropriate infrastructure, or hospital outpatient settings.

The NICE recommendation was supported by a confidential patient access scheme (PAS) discount negotiated between Novartis and NHS England, meaning the actual price paid by the NHS is lower than the list price. NICE's cost-effectiveness analysis found inclisiran acceptable only with this discount applied. The list price in the UK is £1,987.36 per injection (£3,974.72 annually before PAS discount) 8.

The NHS model is often cited as the most integrated approach to inclisiran deployment globally. By embedding the drug within structured lipid pathways rather than leaving access to individual prescriber initiative, the UK aims to reach high-risk patients who have fallen through gaps in conventional lipid management.

Health Canada Approval: 2023

Health Canada authorized Leqvio in July 2023, making Canada the last of the four major markets covered here to grant approval 9. The Canadian indication closely mirrors the US label: adjunct to diet and maximally tolerated statin therapy in adults with HeFH or clinical ASCVD who require additional LDL-C lowering.

The Canadian Drug Expert Committee (CDEC) of CADTH reviewed inclisiran and provided a conditional recommendation for reimbursement, subject to price reduction from the submitted price and alignment with specific clinical criteria. Provincial formulary listings determine actual patient access, and coverage decisions vary by province and territory.

The Canadian label, like the US version, restricts administration to healthcare professionals. The dosing schedule remains identical across all four markets: 284 mg subcutaneously at day 0, day 90, and every 6 months thereafter.

Key Differences Across Regulatory Jurisdictions

The four approvals share the same molecule and dosing regimen but differ in three important ways. First, indication breadth: the EU and UK labels cover primary hypercholesterolemia broadly (including non-familial forms), while the US and Canada restrict the indication to HeFH or established ASCVD. Second, statin background requirements: the EU label permits use in statin-intolerant patients or those for whom statins are contraindicated as standalone therapy, whereas the US label positions inclisiran as an adjunct to maximally tolerated statins 3 6. Third, reimbursement architecture: the UK's centralized commissioning model contrasts sharply with the US system where medical benefit billing under Part B creates distinct access barriers compared to pharmacy-benefit drugs.

None of the four regulatory agencies granted a cardiovascular outcomes claim at the time of initial approval. All approvals were based on LDL-C reduction as a surrogate endpoint. The ORION-4 outcomes trial (expected to report its primary results) will be the key dataset that could lead to supplemental label claims across all four markets 4.

A 2022 analysis published in the Journal of the American College of Cardiology noted: "The twice-yearly dosing of inclisiran offers the potential to improve long-term adherence to PCSK9-targeted therapy, which has been a persistent challenge with injectable monoclonal antibodies requiring more frequent dosing" 5. Adherence data from real-world UK deployment will be important for validating this theoretical advantage.

Where Inclisiran Fits in the Lipid-Lowering Algorithm

Current guidelines from the American Heart Association/American College of Cardiology position PCSK9-targeted therapies (both monoclonal antibodies and inclisiran) as options for patients with ASCVD or HeFH whose LDL-C remains above goal despite maximally tolerated statin therapy plus ezetimibe 10. The 2018 AHA/ACC cholesterol guideline and its 2022 update do not differentiate between inclisiran and monoclonal antibody PCSK9 inhibitors in terms of positioning.

The European Society of Cardiology/European Atherosclerosis Society 2019 dyslipidemia guidelines similarly place PCSK9-targeted agents as third-line options after statins and ezetimibe, with the added consideration that bempedoic acid now occupies a position between ezetimibe and PCSK9-targeted drugs in some treatment algorithms 11.

Choosing between inclisiran and a monoclonal antibody PCSK9 inhibitor is a clinical decision influenced by several factors: patient preference for twice-yearly office-based injections versus more frequent self-injection, insurance coverage and out-of-pocket costs, the clinical setting (patients who reliably attend office visits versus those better served by home administration), and whether the prescriber has the infrastructure for in-office subcutaneous injections.

The 2019 ESC/EAS guidelines state: "For very high-risk patients, an LDL-C reduction of at least 50% from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) are recommended" 11. Inclisiran's approximately 50% LDL-C reduction positions it as a drug that can help many patients reach these targets when added to optimized background therapy.

Safety Profile Across Approval Datasets

The integrated safety analysis from ORION-9, ORION-10, and ORION-11 showed that the most common adverse event was injection-site reaction, reported in 5% of inclisiran-treated patients versus 0.7% on placebo 1. Most reactions were mild (grade 1) and resolved without intervention. No cases of liver toxicity, thrombocytopenia, or renal impairment were attributed to inclisiran at rates exceeding placebo.

Across all three registrational trials, serious adverse events occurred in 22.4% of inclisiran patients and 22.5% of placebo patients, indicating no excess serious safety signal 1 7. Anti-drug antibodies were detected in a small proportion of patients but did not appear to affect LDL-C lowering efficacy or safety.

All four regulatory agencies included injection-site reactions and the potential for hypersensitivity in their respective product labeling. No black-box warnings appear on any of the approved labels. Post-marketing pharmacovigilance continues across all jurisdictions, with periodic safety update reports required by the EMA and FDA adverse-event reporting ongoing.

The long intracellular half-life of inclisiran's RISC-loaded strand means that if an adverse event does occur, the pharmacologic effect cannot be rapidly reversed. This is noted in prescribing information across all markets and is a consideration clinicians weigh when selecting among lipid-lowering agents 3.